共 115 条
[1]
Offit K(2011)Personalized medicine: new genomics, old lessons Hum Genet. 130 3-14
[2]
Chin L(2011)Cancer genomics: from discovery science to personalized medicine Nat Med. 17 297-303
[3]
Andersen JN(2001)Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med. 344 1031-1037
[4]
Futreal PA(2014)Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses Clin Cancer Res 20 4827-4836
[5]
Druker BJ(2012)Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative Clin Cancer Res. 18 6373-6383
[6]
Talpaz M(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 45 228-247
[7]
Resta DJ(2000)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst. 92 205-216
[8]
Peng B(2008)Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience Br J Cancer. 98 1029-1033
[9]
Buchdunger E(2012)Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience Clin Cancer Res. 18 2922-2929
[10]
Ford JM(2016)Cancer therapy directed by comprehensive genomic profiling: a single center study Cancer Res. 76 3690-3701